Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof
A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
1. A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-(4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”) wherein said AV1066 is in the (+) form substantially absent the (−) form.
2. The method of claim 1 comprising administering AV1066 in a dosage of from about 5 mg/kg per day to about 50 mg/kg/day.
3. The method of claim 2 wherein said dosage is from about 10 /mg/kg/day to about 30 mg/kg/day.
4. The method of claim 1 comprising administering AV1066 in a dosage of from about 250 mg/ per day to about 1000 mg/day.
5. The method of claim 4 wherein said dosage is from about 350 mg/day to about 750 mg/day.
6. The method of claim 1 wherein said pain is visceral pain comprising administering AV1066 in a dosage of from about 5 mg/kg per day to about 50 mg/kg/day.
7. The method of claim 6 wherein said dosage is from about 10 /mg/kg/day to about 30 mg/kg/day.
8. The method of claim 6 comprising administering AV1066 in a dosage of from about 250 mg/ per day to about 1000 mg/day.
9. The method of claim 8 wherein said dosage is from about 350 mg/day to about 750 mg/day.
10. The method of claim 1 wherein said pain is neuropathic pain comprising administering AV1066 in a dosage of from about 5 mg/kg per day to about 50 mg/kg/day.
11. The method of claim 10 wherein said dosage is from about 10 /mg/kg/day to about 30 mg/kg/day.
12. The method of claim 10 comprising administering AV1066 in a dosage of from about 250 mg/ per day to about 1000 mg/day.
13. The method of claim 12 wherein said dosage is from about 350 mg/day to about 750 mg/day.
14. The method of claim 1 wherein said AV1066 is in the sodium salt form.
15. The method of claim 1 wherein said AV1066 is in the phosphate salt form.
16. The method of claim 1 wherein said AV1066 is administered in conjunction with a pharmaceutically acceptable carrier.
17. A method for the treatment and/or prevention of hyperalgesia pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-(4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”) wherein said AV1066 is in the (+) form substantially absent the (−) form.